Advertisement Elsevier and Russia's Ural Federal University sign license agreement for Pure - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Elsevier and Russia’s Ural Federal University sign license agreement for Pure

Elsevier has reached an agreement with Russia's Ural Federal University (UrFU) to provide its researchers, faculty members and management with access to Pure, a research information management system to enable evidence-based decisions, promote collaboration, simplify administration and optimize impact.

Pure is part of the Elsevier Research Intelligence portfolio of tools and services.

Over the years, UrFU, one of the leading Russian universities, has focused on increasing the quality and quantity of its research output with the aim of increasing its position in the world research rankings.

With access to Pure, UrFU researchers, faculty members and management can improve transparency in their research processes, monitor and facilitate collaboration and track the university’s research outcomes, including awarded grants, publications and research output and impact.

Furthermore, the customized dashboards and flexible reporting capabilities will help managers make more strategic, evidence-based decisions to improve the university’s performance.

UrFu’s Rector Viktor Koksharov noted that Pure will allow us to share our accomplishments with the global scientific community.

"Centrally collecting research information will give us more insights to enable us to increase the efficiency of research management in the university," Koksharov added.

Elsevier Russia and Belarus regional director Dr Igor Osipov noted the company welcomes the innovative approach UrFu is taking for their future development.

"We are pleased to extend our collaboration with the university and bringing Pure to the Russian market for the first time. We are confident that with access to Pure the university can further optimize their efforts to expand their global reputation," Dr Osipov added.